Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins

摘要: Non-small-cell lung cancer (NSCLC) is the main type of with high mortality rates in worldwide. There a need to identify better biomarkers detect NSCLC at an early stage as this will improve therapeutic effect and patient survival rates. Two lectins (AAL/AAGL AAL2/AANL), which specifically bind tumour-related glycan antigens, were first used enrich serum glycoproteins from patients, benign diseases subjects healthy individuals. The samples investigated by using iTRAQ labelling LC-MS/MS. A total 53 differentially expressed proteins identified quantitative proteomics four (AACT, AGP1, CFB HPX) selected for further verification western blotting. Receiver operating characteristic analysis showed AACT was best candidate diagnosis proteins, 94.1% sensitivity distinguishing tumour Stage (IA+IB) tumour-free (healthy samples, HB). GlcNAcylated detected lectin-based ELISA has advantage clinical application than AACT. can effectively differentiate I HB AUC 0.908 90.9% specificity 86.2%. combination carcinoembryonic antigen (CEA) able differing (AUC=0.914), significantly CEA. also diagnostic efficacy CEA or alone, yielded 0.817 93.1% specificity. Our findings suggest that be promising biomarker NSCLC.